In brief: Agenix files for Canadian trials; Rockeby to appoint Chinese distributor
Tuesday, 31 August, 2004
Brisbane’s Agenix (ASX: AGX, NASDAQ OTC: AGXLY) announced today it had filed a Clinical Trial Application (CTA) with Health Canada in preparation for the Phase II clinical trials of its ThromboView blood clot imaging technology.
This follows last week’s filing of an Investigational New Drug (IND) application for Phase II trials with the US Food and Drug Administration (FDA).
The initial deep vein thrombosis (DVT) trial will involve 11 principal investigators, a core nuclear medicine group and academic and commercial research groups to conduct the trials. Up to 180 suspected DVT patients will take part in the trials.
Rockeby appoint Chinese distributor
Sydney's Rockeby biomed (ASX:RBY) has signed a memorandum of understanding with specialist Chinese women’s medicine and healthcare company, Hua Han Bio-Pharmaceutical for the rollout of its thrush diagnostic CanDia5 throughout mainland China.
Hua Han Bio-Pharmaceutical is listed on Main Board of the Hong Kong Stock Exchange. Hua Han will manage the registration of CanDia5 at its own expense.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
